clinical trial · NCT05864846
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
Tuberous Sclerosis Complex Associated Neuropsychiatric DiseaseCannabidiol Oral Solution [Epidiolex]
brief summary
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.
started
Jun 29, 2023
primary completion
Mar 26, 2026
completion
Mar 26, 2026
last updated
Mar 12, 2026
official title
A Phase 4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuberous Sclerosis Complex
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol